VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported PARIS, June 5, 2024 /PRNewswire/ — Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and…
